High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

Raymond Lenhard, M. M. Oken, J. M. Barnes, Richard L Humphrey, J. H. Glick, M. N. Silverstein

Research output: Contribution to journalArticle

Abstract

The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily x 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty-nine percent of patients experienced leukocyte cell nadirs 2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

Original languageEnglish (US)
Pages (from-to)1456-1460
Number of pages5
JournalCancer
Volume53
Issue number7
DOIs
StatePublished - 1984

Fingerprint

Multiple Myeloma
Cyclophosphamide
Therapeutics
Bone Marrow
Platelet Transfusion
Thrombocytopenia
Hospitalization
Leukocytes
Anti-Bacterial Agents
Pain
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. / Lenhard, Raymond; Oken, M. M.; Barnes, J. M.; Humphrey, Richard L; Glick, J. H.; Silverstein, M. N.

In: Cancer, Vol. 53, No. 7, 1984, p. 1456-1460.

Research output: Contribution to journalArticle

Lenhard, Raymond ; Oken, M. M. ; Barnes, J. M. ; Humphrey, Richard L ; Glick, J. H. ; Silverstein, M. N. / High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. In: Cancer. 1984 ; Vol. 53, No. 7. pp. 1456-1460.
@article{dc16a662cb3a441486889aca6fee0c74,
title = "High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma",
abstract = "The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily x 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43{\%}. This includes a 38{\%} response rate for all previously treated patients and a 29{\%} response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63{\%} was observed, characterized by effective pain relief and improved performance. Sixty-nine percent of patients experienced leukocyte cell nadirs 2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43{\%} of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.",
author = "Raymond Lenhard and Oken, {M. M.} and Barnes, {J. M.} and Humphrey, {Richard L} and Glick, {J. H.} and Silverstein, {M. N.}",
year = "1984",
doi = "10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C",
language = "English (US)",
volume = "53",
pages = "1456--1460",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

AU - Lenhard, Raymond

AU - Oken, M. M.

AU - Barnes, J. M.

AU - Humphrey, Richard L

AU - Glick, J. H.

AU - Silverstein, M. N.

PY - 1984

Y1 - 1984

N2 - The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily x 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty-nine percent of patients experienced leukocyte cell nadirs 2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

AB - The Eastern Cooperative Oncology Group evaluated cyclophosphamide 600 mg/m2 intravenously daily x 4 (total dose each cycle 2400 mg/m2) as an aggressive approach to the treatment of patients with advanced multiple myeloma. The overall objective response rate is 43%. This includes a 38% response rate for all previously treated patients and a 29% response rate for patients refractory to prior therapy with cyclophosphamide. The objective response duration was 3 months and the survival of responding patients 9 months. A subjective response rate of 63% was observed, characterized by effective pain relief and improved performance. Sixty-nine percent of patients experienced leukocyte cell nadirs 2 with a mean time to marrow recovery of 17 days. Thrombocytopenia was less severe but required platelet transfusion in 43% of patients. Bone marrow toxicity was encountered in all patients, and death in aplasia is a significant risk. Strict adherence to entry criteria, and a systematic plan for hospitalization for antibiotic and blood component support is required for treatment with this regimen.

UR - http://www.scopus.com/inward/record.url?scp=0021349078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021349078&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

DO - 10.1002/1097-0142(19840401)53:7<1456::AID-CNCR2820530705>3.0.CO;2-C

M3 - Article

C2 - 6697291

AN - SCOPUS:0021349078

VL - 53

SP - 1456

EP - 1460

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -